doi: 10.1016/j.jacc.2023.12.029.
Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction
Affiliations
- PMID: 38418010
- DOI: 10.1016/j.jacc.2023.12.029
Item in Clipboard
Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction
J Am Coll Cardiol.
.
No abstract available
Similar articles
-
Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.Am Fam Physician. 2021 Jul 1;104(1):96-97. Am Fam Physician. 2021. PMID: 34264618 No abstract available.
-
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.Ann Intern Med. 2024 Mar;177(3):JC31. doi: 10.7326/J24-0008. Epub 2024 Mar 5. Ann Intern Med. 2024. PMID: 38437690 Clinical Trial.
-
Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.J Endocrinol Invest. 2024 May;47(5):1047-1049. doi: 10.1007/s40618-023-02290-2. Epub 2023 Dec 29. J Endocrinol Invest. 2024. PMID: 38157134 No abstract available.
-
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.Curr Opin Cardiol. 2022 Jul 1;37(4):350-355. doi: 10.1097/HCO.0000000000000955. Epub 2022 Feb 16. Curr Opin Cardiol. 2022. PMID: 35175229 Review.
-
Semaglutide: First Global Approval.Drugs. 2018 Feb;78(2):275-284. doi: 10.1007/s40265-018-0871-0. Drugs. 2018. PMID: 29363040 Review.
Cited by
-
Opportunities for General Internal Medicine to Promote Equity in Obesity Care.J Gen Intern Med. 2024 Oct 16. doi: 10.1007/s11606-024-09084-z. Online ahead of print. J Gen Intern Med. 2024. PMID: 39414737
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
